Clinical characteristics and genetics analysis for the ITD of congenital hypothyroidism

Abstract Objectives Iodide transport defect (ITD) is one of the principal causes of congenital hypothyroidism (CH) and its primary molecular mechanism is a mutation of the sodium/iodide symporter (NIS) gene. This study aims to analyse the clinical characteristics and genetic mutations of ITD. Methods The participants were a pair of siblings diagnosed with congenital hypothyroidism. Inductively coupled plasma mass spectrometry was used to determine the concentration of salivary iodine and serum iodine and to calculate their ratio. At the same time, next-generation sequencing (NGS) was applied to detect all exons of congenital hypothyroidism-related genes. All suspicious variants were further validated in the patients and their parents by PCR and Sanger sequencing. Results Both patients were conclusively diagnosed with thyroid iodine transport defect (ITD). NGS identified two variants of the NIS gene in the siblings: c.1021G>A (p.Gly341Arg) with paternal origin and c.1330-2A>C with maternal origin. Both of these variants have not been reported to date. They are predicted to be pathogenic based on these clinical symptoms and comprehensive software analysis. Conclusions This is the first reported family study of congenital hypothyroidism with SLC5A5 mutation in China. Next-generation sequencing technology is an effective means of studying the genetics of congenital hypothyroidism. The therapeutic effect of potassium iodide needs to be further evaluated.

[1]  Carlos P. Modenutti,et al.  A Novel SLC5A5 Variant Reveals the Crucial Role of Kinesin Light Chain 2 in Thyroid Hormonogenesis. , 2021, The Journal of clinical endocrinology and metabolism.

[2]  M. Polak,et al.  High Diagnostic Yield of Targeted Next-Generation Sequencing in a Cohort of Patients With Congenital Hypothyroidism Due to Dyshormonogenesis , 2021, Frontiers in Endocrinology.

[3]  T. Tajima,et al.  Targeted next-generation sequencing for congenital hypothyroidism with positive neonatal TSH screening. , 2020, The Journal of clinical endocrinology and metabolism.

[4]  H. Targovnik,et al.  Defects in protein folding in congenital hypothyroidism , 2019, Molecular and Cellular Endocrinology.

[5]  I. Alonso,et al.  Genetic analyses in a cohort of Portuguese pediatric patients with congenital hypothyroidism , 2019, Journal of pediatric endocrinology & metabolism : JPEM.

[6]  A. Chiesa,et al.  Novel Sodium/Iodide Symporter Compound Heterozygous Pathogenic Variants Causing Dyshormonogenic Congenital Hypothyroidism. , 2019, Thyroid : official journal of the American Thyroid Association.

[7]  J. Nicola,et al.  Implications of Na+/I- Symporter Transport to the Plasma Membrane for Thyroid Hormonogenesis and Radioiodide Therapy , 2018, Journal of the Endocrine Society.

[8]  Carlos P. Modenutti,et al.  A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter. , 2018, Endocrinology.

[9]  A. Kolodkina,et al.  High frequency of mutations in 'dyshormonogenesis genes' in severe congenital hypothyroidism , 2018, PloS one.

[10]  L. Persani,et al.  Genetics and management of congenital hypothyroidism. , 2018, Best practice & research. Clinical endocrinology & metabolism.

[11]  A. Sinusas,et al.  An extremely high dietary iodide supply forestalls severe hypothyroidism in Na+/I− symporter (NIS) knockout mice , 2017, Scientific Reports.

[12]  Cintia E. Citterio,et al.  Iodide handling disorders (NIS, TPO, TG, IYD). , 2017, Best practice & research. Clinical endocrinology & metabolism.

[13]  M. Mitchell,et al.  Unresolved Issues in the Wake of Newborn Screening for Congenital Hypothyroidism. , 2016, The Journal of pediatrics.

[14]  S. Fukata,et al.  Iodide Transport Defect and Breast Milk Iodine , 2016, European Thyroid Journal.

[15]  L. Amzel,et al.  Sodium/Iodide Symporter Mutant V270E Causes Stunted Growth but No Cognitive Deficiency. , 2015, The Journal of clinical endocrinology and metabolism.

[16]  S. Jhiang,et al.  Modulation of Sodium Iodide Symporter in Thyroid Cancer , 2014, Hormones and Cancer.

[17]  N. Carrasco,et al.  The Na+/I- symporter (NIS): mechanism and medical impact. , 2014, Endocrine reviews.

[18]  C. Spitzweg,et al.  Genetics and phenomics of hypothyroidism and goiter due to NIS mutations , 2010, Molecular and Cellular Endocrinology.

[19]  D. van Nostrand,et al.  Radioiodine in the treatment of thyroid cancer. , 2007, Endocrinology and metabolism clinics of North America.

[20]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[21]  C. Ginter,et al.  The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number , 2004, Journal of Cell Science.

[22]  N. Amino,et al.  Congenital hypothyroidism caused by a mutation in the Na+/l− symporter , 1997, Nature Genetics.

[23]  Qing-Rong Liu,et al.  Cloning of the human sodium lodide symporter. , 1996, Biochemical and biophysical research communications.

[24]  Ari J. Wassner Congenital Hypothyroidism. , 2018, Clinics in perinatology.

[25]  B. Czarnocka Thyroperoxidase, thyroglobulin, Na(+)/I(-) symporter, pendrin in thyroid autoimmunity. , 2011, Frontiers in bioscience.